Latest news articles

Added 9 months ago Drug news

FDA approves Jynarque for autosomal dominant polycystic kidney disease.-Otsuka.

Otsuka has announced that the FDA has approved Jynarque (tolvaptan) as the first drug treatment to slow kidney function decline...

Added 1 year ago Drug news

Phase III trial of Samsca slows kidney function decline in polycystic kidney disease.- Otsuka.

In the phase III, multi-center, randomized withdrawal, placebo controlled, double-blind REPRISE trial Samsca (tolvaptan), from Otsuka, slowed kidney function decline...

Added 3 years ago Drug news

NICE recommends Samsca (tolvaptan) for autosomal dominant polycystic kidney disease- Otsuka

NICE recommends Samsca (tolvaptan), from Otsuka, be made available for treating autosomal dominant polycystic kidney disease (ADPKD) in adults with...

Search all news articles for Genitourinary congenital anomalies

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Cystic Fibrosis Knowledge Centre

Cystic Fibrosis Knowledge Centre

View disease awareness information, treatment options and European Cystic Fibrosis Society best practice guidelines.

CDK 4/6 inhibitors in metastatic breast cancer

CDK 4/6 inhibitors in metastatic breast cancer

The CDK 4/6 Inhibitors in Metastatic Breast Cancer Learning Zone provides insights and information for metastatic breast cancer (mBC) and CDK 4/6 signalling. This includes the burden and pathophysiology of the disease, the role of CDK 4/6 in cell proliferation and an overview of the CDK 4/6 inhibitors that have been approved for the management of mBC.

Load more

Journal articles

Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations.

Standard of care therapies for autosomal dominant polycystic kidney disease (ADPKD) may limit morbidity and mortality due to disease-related complications, but they do not delay disease progression.

Added 8 months ago

Is the light at the end of the tunnel nigh? A review of ADPKD focusing on the burden of disease and tolvaptan as a new treatment.

Autosomal dominant polycystic kidney disease (ADPKD) causes pathological cystic changes to the kidney and is characterized by numerous renal and systemic manifestations.

Added 8 months ago

Characteristics of primary nocturnal enuresis in adults: an epidemiological study.

To evaluate the prevalence and characteristics of primary nocturnal enuresis (PNE) in adults in Hong Kong, as there are currently limited epidemiological data in adults.

Added 1 year ago

Search all journal articles for Genitourinary congenital anomalies
My Urology Doc

I am a general urologist and men's health expert in Indianapolis, Indiana, U.S.A. I'm also an avid blogger and heath innovator. My social media brand, My Urology Doc, aims to make the formerly taboo world of urology more fun and appealing.

Men's Health: A Forgotten Topic

Men's health is a forgotten topic. To be honest, we men are mostly to blame. We've clung to our masculine misconceptions and repeatedly refused to engage the healthcare community. Who can blame us, we're invincible and we're going to live forever, right? Well, not exactly. Let's look at some of the reasons men's health is one of the least engaged topics in healthcare.